

IMPACT FACTOR 3.4

Indexed in: PubMed



an Open Access Journal by MDPI

## **Advances of Personalized Medicine for Gastric Cancer**

Guest Editor:

#### Dr. Valeria Merz

1. Digestive Molecular Clinical Oncology Research Unit, Università degli Studi di Verona, 37134 Verona, Italy 2. Medical Oncology Unit, Santa Chiara Hospital, 38122 Trento, Italy

Deadline for manuscript submissions:

closed (15 July 2023)

# Message from the Guest Editor

Dear Colleagues,

Precision medicine is reshaping the paradigm of cancer treatment, and the management of gastric cancer has also recently moved toward a tailored therapeutic approach.

This Special Issue aims to highlight the most recent acquisitions around the molecular and cellular biology of gastric cancer, and it focuses on the most compelling advances in tailoring of systemic therapies in patients affected by this disease. The growing knowledge about the genomic landscape of gastric cancer has paved the way for the development of novel targeted drugs and the identification of relevant predictive factors.

Beyond the introduction of anti-HER2 agents more than ten years ago and, more recently, anti-VEGF drugs, the most promising targets include claudin 18.2 and FGFR, but many trials are ongoing.

Articles investigating genetic and epigenetic drivers or other significantly altered pathways, as well as preclinical or clinical studies focused on the molecular profiling, are welcome.

Dr. Valeria Merz Guest Editor







IMPACT FACTOR 3.4





an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University,

Durham, NC 27710, USA

# **Message from the Editor-in-Chief**

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous*))

### **Contact Us**